Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
251 stopped studies mapped to Endocrine Carcinoma and descendants · 90% state a reason
Over the 251 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00129974 | Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage… | Phase 2 | terminated | Aug 12, 2005 | Tufts Medical Center | failure to accrue | Enrollment / accrual |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be… | Phase 1 | withdrawn | Oct 5, 2015 | National Cancer Institute (NCI) | Other- Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT01758458 | Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma | Phase 1 / Phase 2 | terminated | Jan 1, 2013 | Fred Hutchinson Cancer Center | A Phase I/II study (NCT01758458) is now recruiting | Enrollment / accrual |
| NCT01719861 | Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors | Phase 2 | terminated | Nov 1, 2012 | Joel Neal | Lack of efficacy | Efficacy / futility |
| NCT01640847 | MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of… | Phase 2 | withdrawn | Jul 16, 2012 | Imunon | not stated | Not stated |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic… | Phase 2 | terminated | Oct 24, 2014 | Emory University | Slow accrual | Enrollment / accrual |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously… | Phase 1 / Phase 2 | withdrawn | Jan 22, 2016 | Case Comprehensive Cancer Center | Drug unavailable | Other (stated, no rule matched) |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Phase 1 | terminated | Apr 11, 2013 | Mirna Therapeutics, Inc. | Five immune related serious adverse events | Safety / toxicity |
| NCT01137162 | Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors | — | terminated | Jun 4, 2010 | Stanford University | Low Accrual | Enrollment / accrual |
| NCT02152059 | A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer… | Phase 2 | withdrawn | Jun 2, 2014 | AHS Cancer Control Alberta | contract issues | Other (stated, no rule matched) |
| NCT02351505 | Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer | Phase 2 | terminated | Jan 30, 2015 | Erin Bertino | Low patient accrual | Enrollment / accrual |
| NCT00812266 | Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of… | Phase 3 | terminated | Dec 22, 2008 | Danish Oncological Lung Cancer Group | Slow accrual | Enrollment / accrual |
| NCT00299390 | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer | Phase 2 | terminated | Mar 6, 2006 | Bayer | Since only 1 of the first 10 subjects responded to the study treatment, it was decided to stop the… | Efficacy / futility |
| NCT01159327 | Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction… | Phase 2 | terminated | Jul 9, 2010 | National Cancer Center, Korea | low enrolling participants | Enrollment / accrual |
| NCT00227773 | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | Phase 2 | withdrawn | Sep 28, 2005 | Eastern Cooperative Oncology Group | not stated | Not stated |
| NCT00755157 | Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer | Phase 2 | withdrawn | Sep 18, 2008 | University Hospital of Crete | not stated | Not stated |
| NCT01487499 | Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC)(SCLC) | Phase 3 | terminated | Dec 7, 2011 | University of Florida | Unable to enroll adequate number of participants | Enrollment / accrual |
| NCT01421316 | Hair-sparing Whole Brain Radiotherapy | Phase 2 | terminated | Aug 22, 2011 | University Hospital, Ghent | No reduction in hair loss 1 month after treatment | Other (stated, no rule matched) |
| NCT01832974 | Possible New Therapy for Advanced Cancer | Phase 1 | terminated | Apr 16, 2013 | INSYS Therapeutics Inc | Business decision by the sponsor during Phase 1. | Sponsor / business decision |
| NCT00469469 | Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma | Phase 2 | withdrawn | May 4, 2007 | Dartmouth-Hitchcock Medical Center | unable to enroll subjects into the study | Enrollment / accrual |
| NCT01486459 | A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing…(TULIP) | N/A | terminated | Dec 6, 2011 | Barwon Health | Insufficient recruits | Enrollment / accrual |
| NCT01591512 | A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer | — | terminated | May 4, 2012 | Fujirebio Diagnostics, Inc. | Decision was made by Sponsor to stop the trial. | Other (stated, no rule matched) |
| NCT01886287 | P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome | Phase 2 | terminated | Jun 25, 2013 | H. Lee Moffitt Cancer Center and Research Institute | Slow accrual | Enrollment / accrual |
| NCT01313663 | A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in… | Phase 2 | terminated | Mar 14, 2011 | GlaxoSmithKline | not stated | Not stated |
| NCT01187615 | Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With… | Phase 1 | terminated | Aug 24, 2010 | Bayer | not stated | Not stated |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | Phase 1 | terminated | Mar 26, 2004 | Yale University | not stated | Not stated |
| NCT00084487 | Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or… | Phase 2 | terminated | Jun 11, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00778817 | IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That… | Phase 2 | terminated | Oct 23, 2008 | National Cancer Institute (NCI) | The trial was permanently halted due to futility concerns. | Efficacy / futility |
| NCT00088933 | Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With… | Phase 1 | terminated | Aug 5, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00095693 | Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally… | Phase 2 | terminated | Nov 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01210131 | Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung…(HX4 in SCLC) | N/A | withdrawn | Sep 28, 2010 | Maastricht Radiation Oncology | not stated | Not stated |
| NCT00003514 | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic… | Phase 2 | withdrawn | Jan 27, 2003 | Burzynski Research Institute | not stated | Not stated |
| NCT00084461 | Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | Phase 2 | terminated | Jun 11, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00697476 | Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive… | Phase 1 / Phase 2 | terminated | Jun 13, 2008 | Armando Santoro, MD | insufficient enrollment | Enrollment / accrual |
| NCT01736878 | Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma(SUMMIT) | Phase 2 | withdrawn | Nov 29, 2012 | Eanm Research Ltd | Study was withdrawn due to unanticipated hassle in patient recruitment. | Enrollment / accrual |
| NCT00916669 | A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in… | Phase 2 | withdrawn | Jun 9, 2009 | Massachusetts General Hospital | sponsor withdrew funding prior to patient enrollment | Enrollment / accrual |
| NCT00977561 | A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab… | Phase 2 | terminated | Sep 15, 2009 | Pfizer | See termination reason in detailed description. | Other (stated, no rule matched) |
| NCT00776295 | Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage… | Phase 2 | terminated | Oct 21, 2008 | H. Lee Moffitt Cancer Center and Research Institute | Low accrual | Enrollment / accrual |
| NCT01071434 | Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors | — | terminated | Feb 19, 2010 | Stanford University | PI left | Investigator |
| NCT00002921 | S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer… | Phase 2 | terminated | Jul 30, 2004 | SWOG Cancer Research Network | Permanently Closed Due to Lack of Accrual | Enrollment / accrual |
| NCT01563601 | Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide… | Phase 3 | withdrawn | Mar 27, 2012 | Cephalon | Business Decision | Sponsor / business decision |
| NCT00324558 | Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY) | Phase 2 | terminated | May 11, 2006 | Clinica Universidad de Navarra, Universidad de Navarra | Sponsor stopped due to difficulties to recruit 130 patients required by protocol | Enrollment / accrual |
| NCT00472771 | INNO-206 in Patients With Small Cell Lung Cancer (SCLC) | Phase 2 | withdrawn | May 14, 2007 | CytRx | Terminated due to clinical trial material production delays | Other (stated, no rule matched) |
| NCT00216216 | Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung… | Phase 2 | terminated | Sep 22, 2005 | Hoosier Cancer Research Network | The results from the interim analysis were not favorable to continue this trial. | Efficacy / futility |
| NCT00428597 | A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell… | Phase 3 | terminated | Jan 30, 2007 | Pfizer | Refer to Detailed Description. | Other (stated, no rule matched) |
| NCT00494026 | Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung… | Phase 2 | terminated | Jun 29, 2007 | Eli Lilly and Company | Study stopped early based on interim results of another trial, showing inferior activity of… | Other (stated, no rule matched) |
| NCT00447421 | A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and… | Phase 1 / Phase 2 | terminated | Mar 14, 2007 | Eli Lilly and Company | Interim results of another trial showed inferior activity of treatment | Other (stated, no rule matched) |
| NCT00522639 | Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent…(FDG-PET lung) | Phase 3 | terminated | Aug 30, 2007 | Maastricht Radiation Oncology | Poor accrual | Enrollment / accrual |
| NCT00475657 | Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer | Phase 2 | terminated | May 21, 2007 | Eli Lilly and Company | Terminated due to lack of efficacy | Efficacy / futility |
| NCT00435578 | Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell… | Phase 2 | terminated | Feb 15, 2007 | Threshold Pharmaceuticals | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jun 16, 2017source: clinicaltrials